CCN4 induces IL-6 production through αvβ5 receptor, PI3K, Akt, and NF-κB singling pathway in human synovial fibroblasts.
BACKGROUND
Osteoarthritis (OA) is the most common degenerative joint disease that is involved in the degradation of articular cartilage. The exact etiology of OA is not completely understood. CCN4 is related to up-regulation in the cartilage of patients with osteoarthritis. Previous studies have shown that CCN4 might be associated with the pathogenesis of OA, but the exact signaling pathways in CCN4-mediated IL-6 expression in synovial fibroblasts (SF) are largely unknown. Therefore, we explored the intracellular signaling pathway involved in CCN4-induced IL-6 production in human synovial fibroblast cells.


METHODS
CCN4-induced IL-6 production was assessed with quantitative real-time qPCR and ELISA. The mechanisms of action of CCN4 in different signaling pathways were studied by using Western blotting. Neutralizing antibodies of integrin were used to block the integrin signaling pathway. Luciferase assays were used to study IL-6 and NF-κB promoter activity. Immunocytochemistry was used to examine the translocation activity of p65.


RESULTS
Osteoarthritis synovial fibroblasts (OASFs) showed significant expression of CCN4 and the expression was higher than in normal SFs. OASF stimulation with CCN4 induced concentration- and time-dependent increases in IL-6 production. Pretreatment of OASFs with αvβ5 but not α5β1 and αvβ3 integrin antibodies reduced CCN4-induced IL-6 production. CCN4-mediated IL-6 production was attenuated by PI3K inhibitor (LY294002 and Wortmannin), Akt inhibitor (Akti), and NF-κB inhibitor (PDTC and TPCK). Stimulation of cells with CCN4 also increased PI3K, Akt, and NF-κB activation.


CONCLUSIONS
Our results suggest that CCN4 activates αvβ5 integrin, PI3K, Akt, and NF-κB pathways, leading to up-regulation of IL-6 production. According to our results, CCN4 may be an appropriate target for drug intervention in OA in the future.
Chun-Han
CH
Hou
Chih-Hsin
CH
Tang
Chin-Jung
CJ
Hsu
Sheng-Mon
SM
Hou
Ju-Fang
JF
Liu
D015153:Blotting, Western; D055511:CCN Intercellular Signaling Proteins / Q000378:metabolism*; D002478:Cells, Cultured; D005347:Fibroblasts / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D015850:Interleukin-6 / Q000096:biosynthesis*; D016328:NF-kappa B / Q000276:immunology / Q000378:metabolism; D010003:Osteoarthritis / Q000276:immunology* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000276:immunology / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D019030:Receptors, Vitronectin / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology*; D013583:Synovial Membrane / Q000276:immunology* / Q000378:metabolism; D014162:Transfection
D055511:CCN Intercellular Signaling Proteins; C116396:CCN4 protein, human; C508600:IL6 protein, human; D015850:Interleukin-6; D016328:NF-kappa B; D011518:Proto-Oncogene Proteins; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt